General Information of Drug Transporter (DTP) (ID: DTFI42L)

DTP Name Multidrug resistance-associated protein 2 (ABCC2)
Gene Name ABCC2
UniProt ID
Q92887 (MRP2_HUMAN)
VARIDT ID
DTD0002
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Synonyms ABC30; ABCC2; ATP-binding cassette sub-family C member 2; CMOAT; CMOAT1; CMRP; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; DJS; MRP2
DTP Family ATP-Binding Cassette (ABC) Superfamily
Drug Conjugate Transporter (DCT) Family (ABCC)
Tissue Specificity Expression in the hepatocytes, renal proximal tubule cells, and intestinal epithelia, and expression in the gallbladder, bronchi, and placenta, It is, however, present in brain capillaries of hippocampus specimens from patients with temporal lobe epilepsy, and in malignant tumor cells from renal clear-cell, hepatocellular, ovarian, colorectal, lung, breast, and gastric carcinomas
Sequence
MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSS
TTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYS
RQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILI
FSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS
KFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSG
TKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIG
YLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGET
VNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAIL
STKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFS
QLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMI
SSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLD
IMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNIL
FGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLD
IYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIV
EKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAAS
ITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETG
KVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQR
DMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRI
VNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMF
YVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSW
ITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTS
EIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGI
TCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTII
PQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIG
QRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMD
SDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF
Function This transporter mediates hepatobiliary excretion of numerous organic anions and may function as a cellular cisplatin transporter.
Endogenous Substrate(s) Alkaloids; Bilirubin glucuronides; Cysteinyl leukotrienes; E2 17 beta glucuronide; Epipodophyllotosine; Glutahione conjugates; Glutathione dilsulfide; Hepatic canalicular conjugates; Reduced glutathione; Taruochenodeoxycholate sulfate; Taurolithocholate sulfate; Dehydroepiandrosterone sulfate
TCDB ID
3.A.1.208.2
Gene ID
1244
KEGG Pathway
Antifolate resistance (hsa01523 )
Platinum drug resistance (hsa01524 )
ABC transporters (hsa02010 )
Bile secretion (hsa04976 )
Reactome Pathway
ABC-family proteins mediated transport (R-HSA-382556 )
Defective ABCC2 causes DJS (R-HSA-5679001 )
Aspirin ADME (R-HSA-9749641 )
Paracetamol ADME (R-HSA-9753281 )
Atorvastatin ADME (R-HSA-9754706 )
Heme degradation (R-HSA-189483 )

Molecular Interaction Atlas (MIA) of This DTP

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTP
75 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [1]
Aciclovir DMYLOVR Virus infection 1A24-1D9Z Approved [2]
Adefovir DMM278X Hepatitis B virus infection 1E51.0 Approved [3]
Ampicillin DMHWE7P Bacterial infection 1A00-1C4Z Approved [4]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [5]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [6]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [7]
Cefodizime DMORSGU Bacterial infection 1A00-1C4Z Approved [4]
Ceftriaxone DMCEW64 Bacterial infection 1A00-1C4Z Approved [4]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [8]
Cholic acid DM7OKQV Peroxisomal disorder 5C57 Approved [9]
Ciclosporin DMT2KRV Psoriasis vulgaris EA90 Approved [10]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [4]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [11]
Dehydroepiandrosterone sulfate DM4Q80H Dyspareunia GA12 Approved [12]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [13]
Docetaxel DMDI269 Solid tumour/cancer 2A00-2F9Z Approved [14]
Doxorubicin DMVP5YE Solid tumour/cancer 2A00-2F9Z Approved [15]
Enalapril DMNFUZR Hypertension BA00-BA04 Approved [16]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [4]
Erythromycin DM4K7GQ Bacterial infection 1A00-1C4Z Approved [17]
Estrone sulfate DMVBIZL Menopausal and postmenopausal disorder GA30 Approved [18]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [19]
Ezetimibe DM7A8TW Hypercholesterolaemia 5C80.0 Approved [20]
Fluorescein DMQTFAO Ocular disease 1F00.1Z Approved [21]
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [22]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [23]
Gadobenate dimeglumine DM4VAOG Schizophrenia 6A20 Approved [24]
Gatifloxacin DMSL679 Respiratory tract infection CA45 Approved [25]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [26]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [27]
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [28]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [29]
Irinotecan DMP6SC2 Colorectal cancer 2B91.Z Approved [30]
Leucovorin DMUAZWG Colorectal cancer 2B91.Z Approved [31]
Lopinavir DMITQS0 Human immunodeficiency virus infection 1C62 Approved [32]
Mesalazine DMOL5IU Ulcerative colitis DD71 Approved [33]
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [34]
Mitoxantrone DMM39BF Solid tumour/cancer 2A00-2F9Z Approved [4]
Mycophenolate mofetil DMPQAGE Organ transplant rejection NE84 Approved [35]
Mycophenolic acid DMYTN18 Organ transplant rejection NE84 Approved [36]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [37]
Octreotide DMHIDCJ Acromegaly 5A60.0 Approved [38]
Olamufloxacin DMQ4PKA Bacterial infection 1A00-1C4Z Approved [39]
Olmesartan medoxomil DMWBHRY High blood pressure BA00 Approved [40]
Oxaliplatin DMQNWRD Colorectal cancer 2B91.Z Approved [41]
Paclitaxel DMLB81S Breast cancer 2C60-2C65 Approved [42]
Pemetrexed DMMX2E6 Malignant pleural mesothelioma 2C26.0 Approved [39]
Pemirolast DML97WV Allergic conjunctivitis 9A60.02 Approved [39]
Phenobarbital DMXZOCG Seizure disorder 8A6Z Approved [43]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [44]
Pitavastatin DMJH792 Hyperlipidemia 5C80.Z Approved [45]
Pitavastatin calcium DM1UJO0 Dyslipidemia 5C80-5C81 Approved [4]
Pravastatin DM6A0X7 Hypercholesterolaemia 5C80.0 Approved [46]
Probenecid DMMFWOJ Gout FA25 Approved [47]
Raltitrexed DMT9K8G Rectal adenocarcinoma 2B92 Approved [48]
Regorafenib DMHSY1I Metastatic colorectal cancer 2B91 Approved [49]
Rifampin DMA8J1G Tuberculosis 1B10-1B1Z Approved [50]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [29]
Rosuvastatin DMMIQ7G Hypercholesterolaemia 5C80.0 Approved [51]
Saquinavir DMG814N Human immunodeficiency virus infection 1C62 Approved [52]
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [53]
Succimer DME81IY Metal intoxication NE60 Approved [54]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [55]
Sulfinpyrazone DMEV954 Gout FA25 Approved [56]
Technetium (99MTC) mebrofenin DMUEWM3 Diagnostic imaging N.A. Approved [4]
Telithromycin DMZ4P3A Bacterial infection 1A00-1C4Z Approved [15]
Temocaprilate DMNX2QI High blood pressure BA00 Approved [4]
Temocaprilate DMNX2QI High blood pressure BA00 Approved [3]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [3]
Valsartan DMREUQ6 Hypertension BA00-BA04 Approved [57]
Vasopressin DMQ2FPC Diabetes insipidus 5A61.5 Approved [58]
Vinblastine DM5TVS3 Solid tumour/cancer 2A00-2F9Z Approved [59]
Vincristine DMINOX3 Acute lymphoblastic leukaemia 2A85 Approved [4]
VRX496 DMIO4V5 Acquired immune deficiency syndrome 1C62.3 Approved [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 75 Approved Drug(s)
9 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
Glycyrrhizin DM8M2N3 Influenza virus infection 1E30-1E32 Phase 3 [39]
BQ-123 DM0MO8I Pulmonary arterial hypertension BB01.0 Phase 2 [39]
CKD602 DMW9F1G Solid tumour/cancer 2A00-2F9Z Phase 2 [39]
Glutathione-S-S-glutathione DMJ85FS Ovarian cancer 2C73 Phase 2 [60]
LE-SN38 DMW50NF Colorectal cancer 2B91.Z Phase 2 [61]
PEITC DMOMN31 Prostate cancer 2C82.0 Phase 2 [62]
Epicatechin DMN0EMP Duchenne dystrophy 8C70 Phase 1/2 [63]
Sodium taurocholate DM3GO0J Type-2 diabetes 5A11 Phase 1/2 [64]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Clinical Trial Drug(s)
3 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenolphthalein DM5SICT Constipation DD91.1 Withdrawn from market [65]
Azithromycin/chloroquine DM7G8T0 Bacterial infection 1A00-1C4Z Discontinued in Phase 3 [66]
Rhodamine-123 DMQAK6T Prostate cancer 2C82.0 Discontinued in Phase 1 [67]
------------------------------------------------------------------------------------
3 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha-Zearalenol DMQMAWK Cardiovascular disease BA00-BE2Z Preclinical [68]
Scutellarin DMJT1E5 Cerebrovascular ischaemia 8B1Z Preclinical [69]
Taxifolin DMQJSF9 Ovarian cancer 2C73 Preclinical [70]
------------------------------------------------------------------------------------
11 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aminohippuric acid DMUN54G Discovery agent N.A. Investigative [71]
Bilirubin DMI0V4O Discovery agent N.A. Investigative [72]
CCK-8 DMN0J4W N. A. N. A. Investigative [18]
Chelerythrine DMCP1G9 Discovery agent N.A. Investigative [39]
Genistein-7-glucoside DMMLNTW Solid tumour/cancer 2A00-2F9Z Investigative [4]
Glycocholic acid DM0SXNM Discovery agent N.A. Investigative [73]
N5-methylfolate DML0R9M Discovery agent N.A. Investigative [39]
Phlorizin DMNARGO Discovery agent N.A. Investigative [4]
Talinolol DMRTD16 Discovery agent N.A. Investigative [74]
Tauroursodeoxycholic acid DMFKRQE Discovery agent N.A. Investigative [75]
[3H]estradiol-17beta-glucuronide DM3KJ45 Discovery agent N.A. Investigative [76]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTP

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTP
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 1.29E-14 -3.25E-01 -7.49E-01
Adrenocortical carcinoma 2D11.Z Kidney 6.05E-01 -6.69E-02 -1.18E-01
Alopecia ED70 Skin from scalp 4.03E-01 3.49E-02 1.11E-01
Alzheimer's disease 8A20 Entorhinal cortex 7.16E-01 -1.28E-02 -6.06E-02
Ankylosing spondylitis FA92.0 Pheripheral blood 2.49E-01 1.29E-01 7.94E-01
Aortic stenosis BB70 Calcified aortic valve 8.86E-01 7.20E-03 1.84E-02
Apnea 7A40 Hyperplastic tonsil 3.64E-01 9.84E-02 6.62E-01
Arthropathy FA00-FA5Z Peripheral blood 3.63E-01 4.16E-02 2.24E-01
Asthma CA23 Nasal and bronchial airway 7.82E-01 2.14E-03 4.38E-03
Atopic dermatitis EA80 Skin 2.52E-01 1.05E-02 8.67E-02
Autism 6A02 Whole blood 8.54E-01 -3.99E-02 -1.31E-01
Autoimmune uveitis 9A96 Peripheral monocyte 4.81E-01 4.69E-02 2.89E-01
Autosomal dominant monocytopenia 4B04 Whole blood 2.05E-01 4.07E-01 1.62E+00
Bacterial infection of gingival 1C1H Gingival tissue 6.91E-01 6.87E-03 3.05E-02
Batten disease 5C56.1 Whole blood 7.00E-01 1.86E-01 1.07E+00
Behcet's disease 4A62 Peripheral blood 3.08E-01 7.35E-02 3.54E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 8.63E-01 9.14E-03 5.41E-02
Bladder cancer 2C94 Bladder tissue 9.44E-01 -1.80E-01 -5.06E-01
Breast cancer 2C60-2C6Z Breast tissue 2.95E-07 -2.11E-01 -4.00E-01
Cardioembolic stroke 8B11.20 Whole blood 2.54E-06 6.44E-01 1.49E+00
Cervical cancer 2C77 Cervical tissue 7.81E-01 3.85E-02 1.27E-01
Childhood onset rheumatic disease FA20.Z Peripheral blood 4.19E-01 -8.92E-02 -1.73E-01
Chronic hepatitis C 1E51.1 Whole blood 7.73E-01 -2.06E-02 -1.29E-01
Chronic obstructive pulmonary disease CA22 Lung tissue 3.49E-01 6.59E-02 3.03E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 3.57E-01 -8.50E-02 -2.09E-01
Chronic rhinosinusitis CA0A Sinus mucosa tissue 2.19E-01 0.00E+00 0.00E+00
Colon cancer 2B90 Colon tissue 1.42E-20 2.40E-01 5.69E-01
Coronary artery disease BA80-BA8Z Peripheral blood 2.45E-01 -3.27E-01 -1.24E+00
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 3.39E-01 -9.43E-02 -1.75E-01
Endometriosis GA10 Endometrium tissue 6.57E-01 -7.03E-03 -3.29E-02
Familial hypercholesterolemia 5C80.00 Peripheral blood 8.01E-01 -9.49E-02 -6.06E-01
Familial hypercholesterolemia 5C80.00 Whole blood 4.30E-02 -2.29E-01 -9.10E-01
Gastric cancer 2B72 Gastric tissue 4.48E-02 1.85E-01 9.45E-01
Glioblastopma 2A00.00 Nervous tissue 6.76E-01 2.25E-02 7.43E-02
Glioma 2A00.0Y-2A00.0Z White matter tissue 2.04E-01 -1.77E-01 -5.42E-01
Head and neck cancer 2D42 Head and neck tissue 5.32E-02 -1.36E-01 -2.97E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 1.17E-02 -1.29E-01 -4.98E-01
Huntington's disease 8A01.10 Whole blood 1.38E-01 6.18E-02 4.19E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 1.80E-01 -1.17E-01 -7.13E-01
Immunodeficiency 4A00-4A20 Peripheral blood 5.49E-01 -2.68E-02 -2.25E-01
Influenza 1.00E+30 Whole blood 5.14E-01 1.28E-01 4.45E-01
Interstitial cystitis GC00.3 Bladder tissue 6.75E-01 -2.47E-03 -9.45E-03
Intracranial aneurysm 8B01.0 Intracranial artery 1.25E-03 -3.79E-01 -9.14E-01
Irritable bowel syndrome DD91.0 Rectal colon tissue 5.23E-01 8.97E-03 3.36E-02
Ischemic stroke 8B11 Peripheral blood 6.64E-01 -1.38E-02 -9.45E-02
Juvenile idiopathic arthritis FA24 Peripheral blood 1.46E-02 -1.88E-01 -3.83E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 8.87E-01 1.81E-01 6.06E-01
Lateral sclerosis 8B60.4 Skin 9.30E-01 2.49E-03 1.31E-02
Liver cancer 2C12.0 Liver tissue 3.26E-02 2.25E-02 3.48E-02
Liver failure DB99.7-DB99.8 Liver tissue 1.45E-02 -1.98E+00 -3.61E+00
Lung cancer 2C25 Lung tissue 1.02E-08 -5.12E-02 -2.22E-01
Lupus erythematosus 4A40 Whole blood 7.36E-09 3.25E-01 6.71E-01
Major depressive disorder 6A70-6A7Z Whole blood 5.42E-02 1.01E-01 2.09E-01
Major depressive disorder 6A70-6A7Z Hippocampus 1.85E-02 5.14E-02 3.36E-01
Melanoma 2C30 Skin 3.60E-03 5.12E-02 6.03E-02
Multiple myeloma 2A83.1 Bone marrow 2.22E-01 -1.68E-01 -6.27E-01
Multiple myeloma 2A83.1 Peripheral blood 2.44E-01 6.35E-02 3.90E-01
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 4.24E-01 2.07E-01 6.55E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 8.42E-01 6.53E-04 5.72E-03
Myelofibrosis 2A20.2 Whole blood 5.87E-01 -2.27E-02 -1.39E-01
Myocardial infarction BA41-BA50 Peripheral blood 6.93E-01 9.50E-02 1.25E-01
Myopathy 8C70.6 Muscle tissue 1.38E-01 -1.42E-01 -8.33E-01
Neonatal sepsis KA60 Whole blood 2.04E-05 1.82E-01 6.30E-01
Neuroectodermal tumour 2A00.11 Brain stem tissue 7.79E-04 -8.57E-01 -1.99E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 8.73E-01 3.60E-02 8.80E-02
Obesity related type 2 diabetes 5A11 Omental adipose tissue 1.94E-01 3.14E-01 2.46E+00
Olive pollen allergy CA08.00 Peripheral blood 1.05E-01 -2.11E-01 -1.36E+00
Oral cancer 2B6E Oral tissue 2.89E-03 -2.40E-01 -9.52E-01
Osteoarthritis FA00-FA0Z Synovial tissue 5.68E-01 5.84E-03 1.64E-02
Osteoporosis FB83.1 Bone marrow 6.56E-01 6.43E-02 2.99E-01
Ovarian cancer 2C73 Ovarian tissue 9.91E-01 -4.05E-02 -1.15E-01
Pancreatic cancer 2C10 Pancreas 2.85E-01 -3.85E-01 -9.20E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 6.25E-01 8.95E-02 8.58E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 2.15E-01 8.74E-02 5.78E-01
Pituitary cancer 2D12 Pituitary tissue 1.96E-01 -8.30E-03 -2.10E-02
Pituitary gonadotrope tumour 2D12 Pituitary tissue 2.15E-01 -8.70E-02 -2.24E-01
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 4.68E-01 5.75E-02 3.48E-01
Polycythemia vera 2A20.4 Whole blood 5.58E-03 9.73E-02 5.83E-01
Pompe disease 5C51.3 Biceps muscle 7.81E-01 -8.15E-02 -4.87E-01
Preterm birth KA21.4Z Myometrium 5.00E-01 -1.74E-02 -1.81E-01
Prostate cancer 2C82 Prostate 1.58E-01 -4.23E-01 -7.28E-01
Psoriasis EA90 Skin 7.41E-21 4.03E-01 1.33E+00
Rectal cancer 2B92 Rectal colon tissue 2.34E-03 4.75E-01 1.43E+00
Renal cancer 2C90-2C91 Kidney 5.05E-01 -2.11E-01 -2.62E-01
Retinoblastoma 2D02.2 Uvea 8.84E-02 -7.19E-01 -1.41E+00
Rheumatoid arthritis FA20 Synovial tissue 5.30E-02 3.89E-01 7.37E-01
Rhinovirus infection CA42.1 Nasal epithelium tissue 4.20E-01 -4.75E-02 -1.92E-01
Schizophrenia 6A20 Prefrontal cortex 8.96E-02 1.20E-01 3.25E-01
Schizophrenia 6A20 Superior temporal cortex 8.44E-01 1.30E-02 1.07E-01
Scleroderma 4A42.Z Whole blood 7.59E-01 5.11E-02 1.98E-01
Seizure 8A60-8A6Z Whole blood 8.88E-01 4.47E-02 1.88E-01
Sensitive skin EK0Z Skin 9.43E-01 6.45E-02 3.37E-01
Sepsis with septic shock 1G41 Whole blood 2.71E-24 2.63E-01 7.81E-01
Shwachman-Diamond syndrome 3A70.0 Bone marrow 4.53E-01 4.05E-01 1.36E+00
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 4.40E-02 1.38E-01 6.50E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 7.16E-01 1.73E-01 1.25E+00
Sjogren's syndrome 4A43.2 Salivary gland tissue 7.84E-01 8.30E-03 2.75E-01
Skin cancer 2C30-2C3Z Skin 7.78E-17 2.20E-01 4.83E-01
Thrombocythemia 3B63 Whole blood 6.94E-03 8.23E-02 4.95E-01
Thrombocytopenia 3B64 Whole blood 3.99E-01 1.71E-01 3.53E-01
Thyroid cancer 2D10 Thyroid 1.52E-01 3.61E-02 1.60E-01
Tibial muscular dystrophy 8C75 Muscle tissue 1.49E-06 -6.14E-01 -2.68E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 7.68E-01 5.74E-02 5.34E-01
Type 2 diabetes 5A11 Liver tissue 7.65E-01 -2.63E-02 -1.32E-01
Ureter cancer 2C92 Urothelium 1.26E-01 -1.20E-01 -5.95E-01
Uterine cancer 2C78 Endometrium tissue 1.96E-01 3.38E-02 1.08E-01
Vitiligo ED63.0 Skin 1.33E-02 -3.60E-01 -1.43E+00
------------------------------------------------------------------------------------
⏷ Show the Full List of Expression Under 107 Diseases

Drug Affinity of This DTP Assessed by Cell Line

Approved Drug(s)
Drug Name Highest Status Cell Line Affinity REF
Etoposide Approved Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 617 microM [19]
Irinotecan Approved Bile canalicular membrane vesicles-MRP2 Km = 48.9 microM [61]
Irinotecan Approved Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 90.8 microM [30]
Methotrexate Approved Human embryonic kidney cells (HEK293)-MRP2 Km = 480 microM [77]
Olmesartan medoxomil Approved LLC-PK1 cells-MRP2 Km = 14.9 microM [40]
Valsartan Approved LLC-PK1 cells-MRP2 Km = 30.4 microM [57]
Vinblastine Approved Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 137.3 microM [78]
⏷ Show the Full List of 7 Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Highest Status Cell Line Affinity REF
LE-SN38 Phase 2 Bile canalicular membrane vesicles-MRP2 Km = 180 microM [61]
Investigative Drug(s)
Drug Name Highest Status Cell Line Affinity REF
Aminohippuric acid Investigative Human embryonic kidney cells (HEK293)-MRP2 Km = 880 microM [71]
Aminohippuric acid Investigative Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 2100 microM [79]
Aminohippuric acid Investigative Spodoptera frugiperda (Sf9) cells-MRP2 Km = 5000 microM [79]
Bilirubin Investigative Human embryonic kidney cells (HEK293)-MRP2 Km = 0.7 microM [72]
Bilirubin Investigative Human embryonic kidney cells (HEK293)-MRP2 Km = 0.9 microM [72]
[3H]estradiol-17beta-glucuronide Investigative Human embryonic kidney cells (HEK293)-MRP2 Km = 7.2 microM [76]
⏷ Show the Full List of 6 Investigative Drug(s)

The Drug Therapeutic Target (DTT) Role of This DTP

DTP DTT Name Multidrug resistance-associated protein 2 (ABCC2) DTT Info
DTP DTT Type Literature-reported

References

1 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
2 Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86.
3 Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
5 MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
6 A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
7 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
8 Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
9 Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
10 Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8.
11 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
12 Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23.
13 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
14 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
15 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
16 Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
17 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
18 Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
19 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
20 Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17.
21 Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76.
22 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
23 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
24 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
25 Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010 Aug 16;395(1-2):251-9.
26 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
27 Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007 Nov;46(5):1597-610.
28 Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
29 Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
30 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
31 Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
32 Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
33 Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006 Oct;62(10):871-5.
34 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
35 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
36 C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
37 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
38 P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
39 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
40 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
41 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
42 Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
43 Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15.
44 Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
45 Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
46 Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
47 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9.
48 Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5.
49 Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
50 Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
51 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
52 Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
53 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
54 MRP2 involvement in renal proximal tubular elimination of methylmercury mediated by DMPS or DMSA. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):10-7.
55 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
56 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
57 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
58 Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41.
59 Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
60 Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. Eur J Biochem. 1999 Oct 1;265(1):281-9.
61 Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.
62 Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol. 2005 Aug 15;70(4):640-7.
63 Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res. 2001 Oct;18(10):1420-5.
64 Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
65 Biliary excretion of phenolphthalein sulfate in rats. Pharmacology. 2003 Aug;68(4):177-82.
66 Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004 Mar;48(3):809-14.
67 Characterization of rhodamine-123, calcein and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur J Pharm Sci. 2011 Aug 17;43(5):359-69.
68 ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol Lett. 2009 Oct 28;190(2):215-23.
69 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
70 Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp. Int J Pharm. 2009 Aug 13;378(1-2):1-8.
71 ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
72 Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90.
73 Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003 Jun 27;278(26):23529-37.
74 FDA Drug Development and Drug Interactions
75 Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther. 2007 Feb;320(2):893-9.
76 Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929-37.
77 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
78 Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9.
79 Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004 Nov;15(11):2828-35.